Author: Jessica.F

On October 15, 2021, there was a patent about enzymes.Reference of 3-Bromo-5-fluoro-4-hydroxybenzaldehyde The title of the patent was Fluorescent dye, preparation method therefor and use thereof. And the patent contained the following:

A fluorescent dye I [wherein Ar = (un)substituted arylene or heteroarylene; Y = O or S; R1 = H or alkyl; R2 = halo, OH, or CN], a preparation method therefor and use thereof. For example, II was prepared in a multi-step synthesis. The fluorescent dye has the advantages of sensitivity and specificity to viscosity response, low background fluorescence and the like, and can also be used as a fluorescence activation lighting-type probe for fluorescence labeling, quantification or detection of proteins, enzymes or nucleic acids. The experimental process involved the reaction of 3-Bromo-5-fluoro-4-hydroxybenzaldehyde(cas: 185345-46-4).Reference of 3-Bromo-5-fluoro-4-hydroxybenzaldehyde

The Article related to fluorescent dye preparation fluorescence probe proteins enzyme nucleic acid, Heterocyclic Compounds (More Than One Hetero Atom): Imidazoles and other aspects.Reference of 3-Bromo-5-fluoro-4-hydroxybenzaldehyde

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

On September 30, 2021, Zhang, Dasheng published a patent.HPLC of Formula: 185345-46-4 The title of the patent was Fluorescent dye, preparation method therefor and use thereof. And the patent contained the following:

A fluorescent dye I [wherein Ar = (un)substituted arylene or heteroarylene; Y = O or S; R1 = H or alkyl; R2 = halo, OH, or CN], a preparation method therefor and use thereof. For example, II was prepared in a multi-step synthesis. The fluorescent dye has the advantages of sensitivity and specificity to viscosity response, low background fluorescence and the like, and can also be used as a fluorescence activation lighting-type probe for fluorescence labeling, quantification or detection of proteins, enzymes or nucleic acids. The experimental process involved the reaction of 3-Bromo-5-fluoro-4-hydroxybenzaldehyde(cas: 185345-46-4).HPLC of Formula: 185345-46-4

The Article related to fluorescent dye preparation fluorescence probe proteins enzyme nucleic acid, Heterocyclic Compounds (More Than One Hetero Atom): Imidazoles and other aspects.HPLC of Formula: 185345-46-4

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

On December 10, 2020, Yamada, Yousuke; Takashima, Hajime; Walmsley, David Lee; Ushiyama, Fumihito; Matsuda, Yohei; Kanazawa, Harumi; Yamaguchi-Sasaki, Toru; Tanaka-Yamamoto, Nozomi; Yamagishi, Junya; Kurimoto-Tsuruta, Risa; Ogata, Yuya; Ohtake, Norikazu; Angove, Hayley; Baker, Lisa; Harris, Richard; Macias, Alba; Robertson, Alan; Surgenor, Allan; Watanabe, Hayato; Nakano, Koichiro; Mima, Masashi; Iwamoto, Kunihiko; Okada, Atsushi; Takata, Iichiro; Hitaka, Kosuke; Tanaka, Akihiro; Fujita, Kiyoko; Sugiyama, Hiroyuki; Hubbard, Roderick E. published an article.Formula: C13H11Br The title of the article was Fragment-Based Discovery of Novel Non-Hydroxamate LpxC Inhibitors with Antibacterial Activity. And the article contained the following:

UDP-3-O-acyl-N-acetylglucosamine deacetylase (LpxC) is a zinc metalloenzyme that catalyzes the first committed step in the biosynthesis of Lipid A, an essential component of the cell envelope of Gram-neg. bacteria. The most advanced, disclosed LpxC inhibitors showing antibacterial activity coordinate zinc through a hydroxamate moiety with concerns about binding to other metalloenzymes. Here, we describe the discovery, optimization, and efficacy of two series of compounds derived from fragments with differing modes of zinc chelation. A series was evolved from a fragment where a glycine moiety complexes zinc, which achieved low nanomolar potency in an enzyme functional assay but poor antibacterial activity on cell cultures. A second series was based on a fragment that chelated zinc through an imidazole moiety. Structure-guided design led to a 2-(1S-hydroxyethyl)-imidazole derivative exhibiting low nanomolar inhibition of LpxC and a min. inhibitory concentration (MIC) of 4μg/mL against Pseudomonas aeruginosa, which is little affected by the presence of albumin. The experimental process involved the reaction of 4-(Bromomethyl)-1,1′-biphenyl(cas: 2567-29-5).Formula: C13H11Br

The Article related to non hydroxamate palpxc inhibitor fragment discovery synthesis antibacterial, Heterocyclic Compounds (More Than One Hetero Atom): Imidazoles and other aspects.Formula: C13H11Br

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

On October 1, 2020, Komandla, Mallareddy; Miura, Joanne; Wang, Haixia; Wang, Xiaolun; Lawson, John David; Tyhonas, John published a patent.COA of Formula: C9H9BrO3 The title of the patent was 2-oxo-2,3-dihydro-1H-imidazo[4,5-B]pyridin-6-yl)-4-methylbenzamide derivatives and related heterocycles as RIPK2 inhibitors for the treatment of autoimmune and other diseases. And the patent contained the following:

The invention relates to preparation of dihydroimidazopyridine benzamides(I) and related heterocycles, and pharmaceutically acceptable salts thereof, as RIPK2 inhibitors. Compounds I wherein α is a single bond; β is a double bond; R2 is oxo; R3 is C1-6 alkyl; R4, R5, R6, R7 and R8 each independently is H, halo, C1-4 alkyl, etc.; R9 is C1-6 alkyl, C3-8 haloalkyl, C2-8 heteroalkyl, etc.; etc., are claimed. The example compound II was prepared from the intermediates(also prepared), (procedure given). Compounds I were evaluated for their biol. activities (data given). Compounds I are receptor-interacting protein kinase 2 (RIPK2) inhibitors and can be useful for treating e.g. type I hypersensitivity reactions, autoimmune diseases, inflammatory disorders, cancer and non-malignant proliferative disorders, such as e.g. allergic rhinitis, asthma, atopic dermatitis, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, lupus nephritis, psoriasis, immune thrombocytopenic purpura, inflammatory bowel disease, chronic obstructive pulmonary disease, Sjogren’s syndrome, ankylosing spondylitis, Behcet’s disease, graft vs. host disease, pemphigus vulgaris, idiopathic plasmacytic lymphadenopathy, atherosclerosis, myocardial infarction and thrombosis. The experimental process involved the reaction of 5-Bromo-2-methoxy-4-methylbenzoic acid(cas: 90326-61-7).COA of Formula: C9H9BrO3

The Article related to dihydroimidazopyridine benzamide preparation ripk2 inhibitor autoimmune disease treatment, Heterocyclic Compounds (More Than One Hetero Atom): Imidazoles and other aspects.COA of Formula: C9H9BrO3

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

On January 31, 2020, Zhang, Xinwei; Zhang, Cunlong; Tang, Lin; Lu, Kuan; Zhao, Huan; Wu, Weibin; Jiang, Yuyang published an article.Reference of 2-(2-Bromoethyl)isoindoline-1,3-dione The title of the article was Synthesis and biological evaluation of piperidyl benzimidazole carboxamide derivatives as potent PARP-1 inhibitors and antitumor agents. And the article contained the following:

A series of compounds based on a piperidyl benzimidazole carboxamide structure and tested their PARP-1 inhibitory activity, as well as cellular inhibitory activity. Some of them showed great potency as PARP-1 inhibitors and antitumor activity, which were valuable for further research. In addition, the predicted ADME properties and proposed binding mode with PARP-1 of the compounds were obtained via computational simulation. The experimental process involved the reaction of 2-(2-Bromoethyl)isoindoline-1,3-dione(cas: 574-98-1).Reference of 2-(2-Bromoethyl)isoindoline-1,3-dione

The Article related to alkyl amidobenzimidazolyl piperidine preparation parp inhibition antitumor sar pharmacokinetics, Heterocyclic Compounds (More Than One Hetero Atom): Imidazoles and other aspects.Reference of 2-(2-Bromoethyl)isoindoline-1,3-dione

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

Shao, Rui; Zhao, Haixia; Ding, Shumin; Li, Lianjie; Chen, Chen; Wang, Jian; Shang, Yongjia published an article in 2022, the title of the article was Silver-promoted dearomative [3+4] cycloaddition of anthranils with α-isocyanoacetates: access to benzodiazepines.SDS of cas: 2567-29-5 And the article contains the following content:

The first example of silver-promoted [3+4] cycloaddition of α-isocyanoacetates with anthranils as aromatic Michael accepters, offering access to benzo[d][1,3]diazepinones. Mechanistic studies revealed that an “oxygen migration” rearrangement process was involved in this dearomative cycloaddition reaction. Addnl., benzo[d][1,3]diazepinones were obtained efficiently as well under catalytic conditions. Broad functional groups were well tolerated under mild reaction conditions. The experimental process involved the reaction of 4-(Bromomethyl)-1,1′-biphenyl(cas: 2567-29-5).SDS of cas: 2567-29-5

The Article related to anthranil isocyanoacetate silver promoter dearomative cycloaddition, dihydrobenzodiazepinone carboxylate preparation, Heterocyclic Compounds (More Than One Hetero Atom): Diazepines and other aspects.SDS of cas: 2567-29-5

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

On April 30, 2022, Liang, Xiao; Li, Xue; Zhao, Zhiyuan; Nie, Yiming; Yao, Zefu; Ren, Wandi; Yang, Xinying; Hou, Xuben; Fang, Hao published an article.Category: bromides-buliding-blocks The title of the article was Design, synthesis and biological evaluation of hydantoin derivatives as Mcl-1 selective inhibitors. And the article contained the following:

Herein, authors designed and synthesized a series of hydantoin derivatives I (R1 = H, Ph, OCH2Ph, etc.; R2 = Me, Bn, CH2-Ph-Ph, etc.; R3 = H, 3-NO2-4-Cl) as novel myeloid cell leukemia-1 (Mcl-1) inhibitors based on authors’ previously developed lead compound Among them, compound I (R1 = -OCH2-3,4-di-Cl-Ph; R2 = -CH2-Ph-OCH2-4-Cl-Ph; R3 = 3-NO2-4-Cl) and I (R1 = O(CH2)2-O-3,5-diMe-4-Cl-Ph; R2 = -CH2-Ph-OCH2-4-Cl-Ph; R3 = 3-NO2-4-Cl) exhibited good binding affinities against Mcl-1 with Ki values of 0.49μM and 0.33μM resp. Especially, compound I (R1 = -OCH2-3,4-di-Cl-Ph; R2 = -CH2-Ph-OCH2-4-Cl-Ph; R3 = 3-NO2-4-Cl) exhibited good selectivity over Bcl-xL, whereas compound I (R1 = O(CH2)2-O-3,5-diMe-4-Cl-Ph; R2 = -CH2-Ph-OCH2-4-Cl-Ph; R3 = 3-NO2-4-Cl) possessed good selectivity over both Bcl-2 and Bcl-xL. Furthermore, authors also investigated the effects of these new Mcl-1 inhibitors on cell proliferation, apoptosis and mitochondrial membrane potential, as well as the stability in plasma. The experimental process involved the reaction of 4-(Bromomethyl)-1,1′-biphenyl(cas: 2567-29-5).Category: bromides-buliding-blocks

The Article related to hydantoin preparation antitumor human mcl1 inhibitor apoptosis, apoptosis, cancer, hydantoin derivatives, mcl-1 inhibitors, Heterocyclic Compounds (More Than One Hetero Atom): Imidazoles and other aspects.Category: bromides-buliding-blocks

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

On August 5, 2004, Poupart, Marc-Andre; Beaulieu, Pierre Louis; Rancourt, Jean published a patent.Application In Synthesis of Methyl 5-bromo-2-methoxy-4-methylbenzoate The title of the patent was A preparation of heterocyclic compounds, useful as inhibitors of RNA dependent RNA polymerases, such as hepatitis C virus polymerase. And the patent contained the following:

The invention relates to a preparation of heterocyclic compounds of formula I [wherein: R1 is (cyclo)alkyl, cycloalkenyl, 4 to 7-membered heterocyclic ring, etc.; R2 is halogen or (un)substituted (hetero)aryl; B is N and A is :CH-, or :N-, etc.; B is :C- and A is O, S, or NH, etc.; M1 and M4 are independently selected from CR3; M2 and M3, when not linked to -C(:Y)Z, is CR3; R3 is H, halogen, CN, or azido, etc.], useful as inhibitors of RNA dependent RNA polymerases, particularly those viral polymerases within Flaviviridae family, more particularly to hepatitis C virus (HCV) polymerase. For instance, NS5B RNA dependent RNA polymerase inhibition of pyridinylindole derivative II was determined (compound 101, table 1; IC50 < 1μM). The experimental process involved the reaction of Methyl 5-bromo-2-methoxy-4-methylbenzoate(cas: 39503-58-7).Application In Synthesis of Methyl 5-bromo-2-methoxy-4-methylbenzoate

The Article related to heterocycle preparation hepatitis c virus hcv rna polymerase inhibitor, flaviviridae hepatitis c virus polymerase inhibitor heterocycle preparation, Heterocyclic Compounds (More Than One Hetero Atom): Imidazoles and other aspects.Application In Synthesis of Methyl 5-bromo-2-methoxy-4-methylbenzoate

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

On January 15, 2021, Chen, Xin; Yang, Xi; Mao, Fei; Wei, Jinlian; Xu, Yixiang; Li, Baoli; Zhu, Jin; Ni, Shuaishuai; Jia, Lijun; Li, Jian published an article.Quality Control of 4-(Bromomethyl)-1,1′-biphenyl The title of the article was Development of novel benzimidazole-derived neddylation inhibitors for suppressing tumor growth invitro and invivo. And the article contained the following:

In this study, I [R = H, aminopropane(CO), aminocyclopropane(CO),..etc]. were designed and synthesized based on lead compound CDC to improve the neddylation inhibition and anticancer efficacy. Optimal benzimidazole-derived I [R = (2,4-dichlorophenyl)-1-ethylamino(CO)] displayed superior neddylation inhibition in enzyme assay compared to CDC (IC50 = 5.51μM vs 16.43μM), along with promising target inhibitory activity and killing selectivity in cancer cell. The results of cellular mechanism research combined with tumor growth suppression in human lung cancer cell A549 in vivo, accompanied with docking model, revealed that I [R = (2,4-dichlorophenyl)-1-ethylamino(CO)] had the potential to be developed as a promising neddylation inhibitor for anticancer therapy. The experimental process involved the reaction of 4-(Bromomethyl)-1,1′-biphenyl(cas: 2567-29-5).Quality Control of 4-(Bromomethyl)-1,1′-biphenyl

The Article related to benzimidazolyl methylbiphenylyl tetrazole preparation antitumor agent sar enzyme inhibitor, anticancer, benzimidazole-derived inhibitor, neddylation, cullin1-nedd8, Heterocyclic Compounds (More Than One Hetero Atom): Imidazoles and other aspects.Quality Control of 4-(Bromomethyl)-1,1′-biphenyl

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

On July 21, 2022, Yang, Dun; Zhang, Jing; Zhang, Shenqiu; Allen, Thaddeus; Shi, Qiong; Nimishetti, Naganna; Huang, Jian; Li, Hongmei; Yang, Chenglu published a patent.Related Products of 259231-26-0 The title of the patent was Preparation of fused azepine compounds and their use in the treatment of cancer. And the patent contained the following:

The invention relates to fused azepines of formula I and pharmaceutically acceptable salts thereof; their preparation and use in the treatment of cancer. Compounds of formula I, wherein X is O and S; ring A is (un)substituted Ph, (un)substituted 6-membered heteroaryl; L is a bond, CO, SO2, etc.; each R1 is independently halo, CN, (un)substituted Ph, etc.; each R2 is H, CN, (un)substituted Ph, etc.; each R3 is (un)substituted Ph, (un)substituted heteroaryl, (un)substituted 3- to 7-membered carbocyclyl, etc.; m = 0 – 4; p = 0 – 5; and pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by condensation of Me 5-hydroxy-2-oxo-2,3-dihydro-1H-benzo[b]azepine-4-carboxylate with (bromomethyl)benzene. The invention compounds were evaluated for their anticancer activities (some data given). The experimental process involved the reaction of 2-Bromo-4-(bromomethyl)-1-methylbenzene(cas: 259231-26-0).Related Products of 259231-26-0

The Article related to fused azepine treatment cancer preparation, Heterocyclic Compounds (One Hetero Atom): Higher-Membered Rings and other aspects.Related Products of 259231-26-0

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary